Literature DB >> 1610970

Heterogeneity in the clastogenic response to X-rays in lymphocytes from ataxia-telangiectasia heterozygotes and controls.

J K Wiencke1, D W Wara, J B Little, K T Kelsey.   

Abstract

A coded analysis of X-ray-induced chromatid aberrations in lymphocyte cultures from 45 control individuals and 19 ataxia-telangiectasia (A-T) heterozygotes was performed. The distribution of chromatid breaks induced in the late G2 portion of the cell cycle by 60 cGy of X-rays appeared bimodal in the study population. In six controls (13 percent) and in 12 of 19 (63 percent) A-T heterozygotes, the yields of X-ray-induced breaks observed were within the higher mode of the distribution. However, lymphocytes from A-T heterozygotes sensitive to the induction of chromatid breaks by 60 cGy did not contain increased numbers of aberrations following exposure to 20 cGy. The radio-resistant inhibition of DNA synthesis that occurs in A-T homozygotes was not observed in heterozygotes. Co-cultivation experiments showed an increased G2 delay in lymphocytes from an A-T heterozygote whose lymphocytes contained increased X-ray-induced chromatid breaks. The results show a significant association of A-T heterozygosity with G2 chromosomal sensitivity (P less than 0.001; Wilcoxon rank sum test). The measurement of X-ray-induced breaks, however, failed to identify 37 percent of A-T heterozygotes tested. The predicted prevalence of increased sensitivity to X-rays in controls is approximately three- to 30-fold greater than the estimated frequency of A-T heterozygotes in the general population. Therefore, although the increased sensitivity to X-ray-induced chromatid breaks appears to be associated with the A-T-gene, it is not a reliable indicator of A-T heterozygosity. Genetic or environmental factors other than the A-T gene also must be involved in the increased clastogenic response.

Entities:  

Mesh:

Year:  1992        PMID: 1610970     DOI: 10.1007/bf00124257

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  41 in total

1.  Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene.

Authors:  K K Sanford; R Parshad; F M Price; G M Jones; R E Tarone; L Eierman; P Hale; T A Waldmann
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

2.  Radiosensitivities of ten apparently normal human diploid fibroblast strains to cell killing, G2-phase chromosomal aberrations, and cell cycle delay.

Authors:  H Nagasawa; J B Little
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

3.  Influence of ataxia telangiectasia gene dosage on bleomycin-induced chromosome breakage and inhibition of replication in human lymphoblastoid cell lines.

Authors:  P H Kohn; K H Kraemer; J K Buchanan
Journal:  Exp Cell Res       Date:  1982-02       Impact factor: 3.905

4.  G2 chromosomal radiosensitivity in families with ataxia-telangiectasia.

Authors:  Y Shiloh; R Parshad; M Frydman; K K Sanford; S Portnoi; Y Ziv; G M Jones
Journal:  Hum Genet       Date:  1989-12       Impact factor: 4.132

5.  Malignant neoplasms in the families of patients with ataxia-telangiectasia.

Authors:  M Swift; L Sholman; M Perry; C Chase
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

6.  Chromosomal radiosensitivity during the G2 cell-cycle period of skin fibroblasts from individuals with familial cancer.

Authors:  R Parshad; K K Sanford; G M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Identification of ataxia telangiectasia heterozygotes by flow cytometric analysis of X-ray damage.

Authors:  N S Rudolph; H Nagasawa; J B Little; S A Latt
Journal:  Mutat Res       Date:  1989-03       Impact factor: 2.433

8.  Chromosomal radiosensitivity of ataxia telangiectasia cells at different cell cycle stages.

Authors:  A T Natarajan; M Meyers
Journal:  Hum Genet       Date:  1979-11-01       Impact factor: 4.132

9.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

10.  G2 chromosomal radiosensitivity of ataxia-telangiectasia heterozygotes.

Authors:  R Parshad; K K Sanford; G M Jones; R E Tarone
Journal:  Cancer Genet Cytogenet       Date:  1985-01-01
View more
  4 in total

1.  Transcriptional Dynamics of DNA Damage Responsive Genes in Circulating Leukocytes during Radiotherapy.

Authors:  Lourdes Cruz-Garcia; Farah Nasser; Grainne O'Brien; Jakub Grepl; Volodymyr Vinnikov; Viktor Starenkiy; Sergiy Artiukh; Svetlana Gramatiuk; Christophe Badie
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

2.  Individual Radiosensitivity Assessment of the Families of Ataxia-Telangiectasia Patients by G2-Checkpoint Abrogation.

Authors:  Asghar Aghamohammadi; Seyed M Akrami; Marjan Yaghmaie; Nima Rezaei; Gholamreza Azizi; Mehdi Yaseri; Hassan Nosrati; Majid Zaki-Dizaji
Journal:  Sultan Qaboos Univ Med J       Date:  2019-03-28

3.  Assessment of targeted and non-targeted responses in cells deficient in ATM function following exposure to low and high dose X-rays.

Authors:  Anne Kiuru; Meerit Kämäräinen; Sirpa Heinävaara; Katri Pylkäs; Kim Chapman; Armi Koivistoinen; Teuvo Parviainen; Robert Winqvist; Munira Kadhim; Virpi Launonen; Carita Lindholm
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

4.  The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Authors:  Marie Eliade; Jeremy Skrzypski; Amandine Baurand; Caroline Jacquot; Geoffrey Bertolone; Catherine Loustalot; Charles Coutant; France Guy; Pierre Fumoleau; Yannis Duffourd; Laurent Arnould; Alexandra Delignette; Marie-Martine Padéano; Côme Lepage; Géraldine Raichon-Patru; Axelle Boudrant; Marie-Christine Bône-Lépinoy; Anne-Laure Villing; Aurélie Charpin; Karine Peignaux; Sandy Chevrier; Frédérique Vegran; François Ghiringhelli; Romain Boidot; Nicolas Sevenet; Sarab Lizard; Laurence Faivre
Journal:  Oncotarget       Date:  2017-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.